Search
Nivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsOmega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawnThe omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. … The increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl esters.
Stavudine
go.drugbank.com/drugs/DB00649ApprovedInvestigationalA dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
Mixtures: COVIRO ® LSSugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigationalSugemalimab is a fully human, full-length anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (of the IgG4 isotype) discovered by CStone Pharmaceuticals. … [L53333] The drug achieves this through a dual mechanism of action involving binding to the programmed cell death-ligand 1 (PD-L1) and also through inducing antibody-dependent cellular phagocytosis.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsBNT162B2 Omicron (LP.8.1)
go.drugbank.com/drugs/DB23337ApprovedBNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19. … [L53723] It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2.[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025.
Synonyms: BNT162B2 Omicron (LP.8.1)Calcium carbonate
go.drugbank.com/drugs/DB06724ApprovedInvestigationalCalcium carbonate may also be used as a nutritional supplement or to treat hypocalcemia. … It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin.
Mixtures: L-Methyl PNV DHA, Ni-C-E-LE PlusProducts: L B T A, L D T AllApixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic
Categories: Factor Xa Inhibitors, Direct factor Xa inhibitorsProducts: Apixaban 1A Pharma 5 mg – Filmtabletten, Apixaban 1A Pharma 2,5 mg – FilmtablettenPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalPenpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [A273848] In order to further reduce the risk of toxicities and improve efficacy, penpulimab was designed with Fc mutations in order to eliminate Fc receptor and complement-mediated effector function,
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsDrospirenone
go.drugbank.com/drugs/DB01395ApprovedInvestigationalDrospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. … Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events.
Mixtures: LÍA, Lo-ZumandiminePantothenic acid
go.drugbank.com/drugs/DB01783ApprovedInvestigationalNutraceuticalVet approvedPantothenic acid, also called pantothenate or vitamin B5 (a B vitamin), is a water-soluble vitamin discovered by Roger J. Williams in 1919. … Only the dextrorotatory (D) isomer of pantothenic acid possesses biological activity. while the levorotatory (L) form may antagonize the effects of the dextrorotatory isomer.
Mixtures: Formula Lf, Formula F L W